Get started
Author

Evgenia Verrou

Longitudinal Cohort Study of Risk Factors in Cancer Patients of Bisphosphonate-Related Osteonecrosis of the Jaw
2009 · Konstantinos Vahtsevanos, Athanassios Kyrgidis, et al. · Journal of Clinical Oncology · 470
Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single‐centre experience in 303 patients
2006 · Kostas Zervas, Evgenia Verrou, et al. · British Journal of Haematology · 296
Bortezomib reduces serum dickkopf‐1 and receptor activator of nuclear factor‐κB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma
2006 · Evangelos Terpos, Deborah J. Heath, et al. · British Journal of Haematology · 222
PDF
Natural History of Osteonecrosis of the Jaw in Patients With Multiple Myeloma
2008 · Ashraf Badros, Evangelos Terpos, et al. · Journal of Clinical Oncology · 146
PDF
Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: A report of the Greek myeloma study group in 97 patients
2014 · Eirini Katodritou, Evangelos Terpos, et al. · American Journal of Hematology · 74
PDF
Treatment with bortezomib‐based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group
2013 · Eirini Katodritou, Evangelos Terpos, et al. · American Journal of Hematology · 74
PDF
Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration
2009 · E. Terpos, E. Katodritou, et al. · Haematologica · 71
PDF
Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group
2018 · Eirini Katodritou, Evangelos Terpos, et al. · Blood Cancer Journal · 57
PDF
Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience
2015 · Eirini Katodritou, Evangelos Terpos, et al. · Annals of Hematology · 56
Extramedullary (EMP) relapse in unusual locations in multiple myeloma: Is there an association with precedent thalidomide administration and a correlation of special biological features with treatment and outcome?
2009 · E. Katodritou, V. Gastari, et al. · Leukemia Research · 46
Real‐life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B‐cell lymphomas
2021 · Maria Dimou, Sotirios G. Papageorgiou, et al. · Hematological Oncology · 37
Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: Do specific cytogenetic and immunophenotypic characteristics influence treatment outcome?
2008 · Eirini Katodritou, Evgenia Verrou, et al. · Leukemia Research · 37
Improved survival of patients with primary plasma cell leukemia with VRd or daratumumab‐based quadruplets: A multicenter study by the Greek myeloma study group
2023 · Eirini Katodritou, Efstathios Kastritis, et al. · American Journal of Hematology · 36
PDF
Erythropoiesis stimulating agents are associated with reduced survival in patients with multiple myeloma
2008 · Eirini Katodritou, Evgenia Verrou, et al. · American Journal of Hematology · 31
Hypochromic erythrocytes (%): a reliable marker for recognizing iron-restricted erythropoiesis and predicting response to erythropoietin in anemic patients with myeloma and lymphoma
2007 · Eirini Katodritou, Evangelos Terpos, et al. · Annals of Hematology · 28
Bortezomib is an effective agent for MDS/MPD syndrome with 5q− anomaly and thrombocytosis
2006 · Evangelos Terpos, Evgenia Verrou, et al. · Leukemia Research · 27
Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study “REBUILD”
2022 · Evangelos Terpos, Ioannis Ntanasis-Stathopoulos, et al. · Cancers · 26
PDF
Successful treatment of extramedullary gastric plasmacytoma with the combination of bortezomib and dexamethasone: First reported case
2007 · Eirini Katodritou, Charalambos Kartsios, et al. · Leukemia Research · 25
Central nervous system multiple myeloma: A real‐world multi‐institutional study of the Greek Myeloma Study Group
2024 · Eirini Katodritou, Dimitra Dalampira, et al. · American Journal of Hematology · 23
PDF
A proposed index of diffuse bone marrow [18F]-FDG uptake and PET skeletal patterns correlate with myeloma prognostic markers, plasma cell morphology, and response to therapy
2020 · A. Paschali, E. Panagiotidis, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 21
Evaluation of regulatory T cells (Tregs) alterations in patients with multiple myeloma treated with bortezomib or lenalidomide plus dexamethasone: correlations with treatment outcome
2019 · Christina Hadjiaggelidou, Evdokia Mandala, et al. · Annals of Hematology · 21
Tumor‐primed natural killer cells from patients with multiple myeloma lyse autologous, NK‐resistant, bone marrow‐derived malignant plasma cells
2011 · Eirini Katodritou, Evangelos Terpos, et al. · American Journal of Hematology · 21
PDF
Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide‐exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA
2024 · Evangelos Terpos, Ioannis Ntanasis‐Stathopoulos, et al. · American Journal of Hematology · 19
PDF
Real‐world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: A study of the Greco‐Israeli collaborative myeloma working group
2020 · Eirini Katodritou, Efstathios Kastritis, et al. · American Journal of Hematology · 18
PDF
Sequential evaluation of serum hepcidin in anemic myeloma patients: Study of correlations with myeloma treatment, disease variables, and anemia response
2009 · Eirini Katodritou, Tomas Ganz, et al. · American Journal of Hematology · 18
Works count: 101
Citation count: 2,075
H-index: 21
I10-index: 31
Year
Topic
Type